Department of Medical Parasitology and Mycology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Medical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Mycoses. 2022 Aug;65(8):784-793. doi: 10.1111/myc.13477. Epub 2022 Jun 19.
Candida auris is a drug-resistant pathogen with several reported outbreaks. The treatment of C. auris infections is difficult due to a limited number of available antifungal drugs. Thus, finding alternative drugs through repurposing approaches would be clinically beneficial. A systematic search in PubMed, Scopus and Web of Science databases, as well as Google Scholar up to 1 November 2021, was conducted to find all articles with data regarding the antifungal activity of non-antifungal drugs against the planktonic and biofilm forms of C. auris. During database and hand searching, 290 articles were found, of which 13 were eligible for inclusion in the present study. Planktonic and biofilm forms have been studied in 11 and 8 articles (with both forms examined in 6 articles), respectively. In total, 22 and 12 drugs/compounds have been reported as repositionable against planktonic and biofilm forms of C. auris, respectively. Antiparasitic drugs, with the dominance of miltefosine, were the most common repurposed drugs against both forms of C. auris, followed by anticancer drugs (e.g. alexidine dihydrochloride) against the planktonic form and anti-inflammatory drugs (e.g. ebselen) against the biofilm form of the fungus. A collection of other drugs from various classes have also shown promising activity against C. auris. Following drug repurposing approaches, a number of drugs/compounds from various classes have been found to inhibit the planktonic and biofilm forms of C. auris. Accordingly, drug repurposing is an encouraging approach for discovering potential alternatives to conventional antifungal agents to combat drug resistance in fungi, especially C. auris.
耳念珠菌是一种具有多种报道性爆发的耐药病原体。由于可用的抗真菌药物数量有限，耳念珠菌感染的治疗较为困难。因此，通过重新利用方法寻找替代药物在临床上是有益的。我们在 PubMed、Scopus 和 Web of Science 数据库以及 Google Scholar 中进行了系统检索，截至 2021 年 11 月 1 日，检索了所有关于非抗真菌药物对耳念珠菌浮游和生物膜形式的抗真菌活性的数据的文章。在数据库和手工检索过程中，发现了 290 篇文章，其中有 13 篇符合纳入本研究的标准。分别有 11 篇和 8 篇文章研究了浮游和生物膜形式（有 6 篇文章同时研究了这两种形式）。总共报道了 22 种和 12 种药物/化合物可重新用于治疗耳念珠菌的浮游和生物膜形式，分别。抗寄生虫药物（以米替福新为主）是针对耳念珠菌两种形式最常用的重新利用药物，其次是针对浮游形式的抗癌药物（如盐酸阿比朵尔）和针对生物膜形式的抗炎药物（如依布硒啉）。来自不同类别的其他一系列药物也显示出对耳念珠菌有良好的活性。通过药物再利用方法，已经发现来自不同类别的许多药物/化合物可以抑制耳念珠菌的浮游和生物膜形式。因此，药物再利用是一种有希望的方法，可以发现潜在的替代传统抗真菌药物的方法来对抗真菌的耐药性，特别是耳念珠菌。
